Furthering Pfizer's Global Anti-Infectives Leadership
Since our work with penicillin in the 1940s, Pfizer has actively developed innovative medicines and vaccines, and created tools, policies and programs to address the evolving needs of patients and physicians in infectious diseases.
Today, Pfizer is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products across the globe.
Our portfolio includes anti-infective medicines that help address critical antimicrobial resistance (AMR) needs in difficult-to-treat infections, such as treatment of Gram-negative bacterial infections and invasive fungal infections.
We are also committed to the research and development of medicines and vaccines to treat and help prevent infections caused by resistant pathogens.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families